Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 dose expansion clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 dose escalation clinical trial. It also involves in developing two earlier stage preclinical candidates, including XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Mersana Therapeutics Inc.

Mersana Therapeutics (MRSN) has disclosed a new risk, in the Corporate Activity and Growth category. Mersana Therapeutics faces significant busines...

Mersana Therapeutics Faces High Stakes with Potential Day One Biopharmaceuticals Merger Delays

Mersana Therapeutics ( ($MRSN) ) has released its Q3 earnings. Here is a breakdown of the information Mersana Therapeutics presented to its investo...

Mersana Therapeutics to be Acquired by Day One

Mersana Therapeutics received a Hold rating and price target from William Blair analyst Andy Hsieh today. Hsieh covers the Healthcare sector, focus...

William Blair downgrades Mersana Therapeutics (MRSN) to a Hold

Traders will find all of the latest stock market stories worth reading about on Thursday in our daily wrap-up.


	A	B	C	D
1	Symbol	Price	Change	Volume
2	MRSN	$27.30	-0.76%	117.27K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MRSN	$27.30	-0.8%	117.27K
3
4
5
6

MRSN

MRSN

Get Mersana Therapeutics Inc. Data in Excel

Get Mersana Therapeutics Inc. Data in Excel